City Therapeutics broke cover in October with a $135 million Series A and the opportunity for executive chairman John ...

Marea Therapeutics reports MAR001 reduced remnant cholesterol by ~50% in Phase 2a trial; plans Phase 2b within 6 months.

T cell engagers are having a moment, much like antibody-drug conjugates have for the past two years. The cell-depleting ...

Repare Therapeutics pauses gynecologic cancer drugs lunresertib & camonsertib, shifts focus to early-stage assets RP-1664 & RP-3467 amid cost-cutting measures.

Shoreline Biosciences, a gene editing and cell therapy biotech, has let go of staffers dedicated to a cell therapy project ...

IGM Biosciences announced plans to stay afloat by focusing its resources on a clinical-stage autoimmune asset. Now it's ...

Boston-area start­up Me­di­ar Ther­a­peu­tics is team­ing up with Eli Lil­ly on a new drug for id­io­path­ic pul­monary fi­bro­sis.

As Bayer awaits an FDA decision on its non-hormonal treatment for hot flashes caused by menopause, it's unveiling new results ...

A Dutch biotech cre­at­ing nasal sprays to pro­tect against the flu and coro­n­avirus has raised an ad­di­tion­al $70 ...

Catalyst Therapeutics' controversial, $375,000 rare autoimmune disease drug now won't face generic competition from Teva ...

A2 Bio­ther­a­peu­tics has raised $80 mil­lion to run three ex­per­i­men­tal CAR-T pro­grams for sol­id tu­mor can­cers. The ...

Versant Ventures' latest biotech emerged on Thursday morning with a $62 million Series A from Bristol Myers Squibb, AbbVie ...